|Venture Round, 6/08 |
The Texas Emerging Technology Fund
|Series A, 11/09 |
Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.